½ÃÀ庸°í¼­
»óǰÄÚµå
1463830

À¯·´ÀÇ ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® ¸®Æ÷Æ® °ÔÀç ¹üÀ§ : ÀÎÅÍÆäÀ̽ºº°, ¾ÖÇø®ÄÉÀ̼Ǻ°, ¿ëµµº°, »çÀÌÁ, ¼ÒÀ纰, Á¦Ç° À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°

Europe Noninvasive Ventilation Masks Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Interfaces, Application, Usage, Size, Material, Product Type, End User, and Country

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯·´ÀÇ ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀåÀº 2022³â 7¾ï 1,983¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 10¾ï 7,668¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, 2022-2030³âÀÇ CAGRÀº 5.2%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºñħ½À¼º ȯ±â(NIV)¶õ ±â°ü³» ±âµµ¸¦ ÇÊ¿ä·Î ÇÏÁö ¾Ê´Â ÆäÀ̽º ¸¶½ºÅ©¸¦ ÅëÇÑ »ê¼Ò °ø±Þ(ÀΰøÈ£Èí º¸Á¶)À» ¸»Çϸç, NIV´Â È£Èí ÀÛ¾÷ÀÇ °¨¼Ò¿Í °¡½º ±³È¯À» °³¼±ÇÏ¿© ±âÁ¸ÀÇ ±â°è½Ä ÀΰøÈ£Èí¿¡ ÇÊÀûÇÏ´Â »ý¸®Àû ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ ÁßÀç´Â ¸¸¼ºÆó¼â¼ºÆóÁúȯ, ½ÉÀμº ÆóºÎÁ¾ ¹× »ó±âµµ ¿Ü»ó, ÀΰøÈ£Èí±â °ü·Ã Æó·Å, È£Èí±Ù·ÂÀúÇÏ, ºÎºñµ¿¿°°ú °°Àº ÇÕº´ÁõÀ» µ¿¹ÝÇÏÁö ¾Ê´Â ±âŸ È£Èí±â ÁúȯÀÇ È£ÈíºÎÀü¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¼ö³â°£ À¯·´ÀÇ ºñħ½ÀÀû ÀΰøÈ£Èí±â ½ÃÀå ¿¹Ãø¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

COPD À¯º´·üÀÇ »ó½ÂÀÌ À¯·´ÀÇ ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁø

¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)Àº °¡Àå ½É°¢ÇÑ °øÁߺ¸°Ç ¹®Á¦ Áß ÇϳªÀÔ´Ï´Ù. µ¶ÀÏ ±¹¸³ÀÇÇеµ¼­°üÀÌ 2022³â¿¡ ¹ßÇ¥ÇÑ ³í¹® "Effectiveness of a home telemonitoring program for patients with chronic obstructive pulmonary disease in Germany"¿¡ µû¸£¸é µ¶ÀÏ¿¡¼­ 6¾ï ¸íÀÇ COPD ȯÀÚ°¡ º¸°íµÇ¾ú½À´Ï´Ù. ´Â 600¸¸ ¸íÀÇ COPD ȯÀÚ°¡ º¸°íµÇ¾úÀ¸¸ç, 2021³â ¹ßÇ¥µÈ "What knows a frail Swiss population about chronic obstructive pulmonary disease?"¶ó´Â ³í¹®¿¡ µû¸£¸é ½ºÀ§½º¿¡¼­´Â ¾à 40¸¸ ¸íÀÌ COPD¸¦ ¾Î°í ÀÖ¾ú½À´Ï´Ù.

Áúº´ ¾ÇÈ­, °úÈ£Èí¼º È£Èí °ï¶õ, È£Èí ºÎÀüÀ¸·Î °íÅë¹Þ´Â ±âÃÊ COPD ȯÀÚ´Â ºñ ħ½ÀÀû Àΰø È£Èí(NIV)À¸·Î Ä¡·áÇÒ °¡´É¼ºÀÌ ³ôÀ¸¸ç, NIV´Â È£Èí ±ÙÀ°¿¡ ´ëÇÑ ¾Ð¹ÚÀ» È¿°úÀûÀ¸·Î ¿ÏÈ­Çϰí, Á¶¼ö¸¦ Áõ°¡½Ã۰í, È£Èí ¼ö¸¦ ÁÙÀ̰í, Ⱦ°Ý¸· È£Èí ÀÛ¾÷À» ÁÙÀ̰í, »ê¼Ò °ø±ÞÀ» °³¼±Çϰí, °úÈ£ÈíÀ» ÁÙÀ̰í, È£Èí °ï¶õÀ» °³¼±ÇÕ´Ï´Ù. COPD´Â Ä¡·á°¡ Áï½Ã °¡¿ªÀûÀ̰í Ãß°¡ Áö¿øÀ» Á¦°øÇÒ ¼ö ÀÖÀ¸¹Ç·Î NIV¿¡ ÀÌ»óÀûÀÔ´Ï´Ù.

NIV´Â COPD ȯÀÚÀÇ ±â°ü³» »ð°ü·ü, ÀÔ¿ø ±â°£, ±â°èȯ±â ÇÕº´Áõ, »ç¸Á·üÀ» °¨¼Ò½Ãŵ´Ï´Ù. ÃÖ±Ù ÀÓ»óÁø·áÁöħÀº NIV¸¦ COPDÀÇ ±Þ¼ºÈ£ÈíºÎÀü(ARF) Ä¡·áÀÇ 1Â÷ ¼±Åà ȯ±â¿ä¹ýÀ¸·Î ÃßõÇϰí ÀÖÀ¸¸ç, NIV ¸¶½ºÅ©´Â COPD¿Í È£ÈíºÎÀüÀ» ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ Ä¡·á¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

NIV´Â È£ÈíºÎÀüÀ» µ¿¹ÝÇÑ COPD ¾ÇÈ­ ȯÀÚÀÇ »ð°ü ¹× »ç¸Á·ü °¨¼Ò¿¡ µµ¿òÀÌ µË´Ï´Ù. ¸¶½ºÅ©ÀÇ À¯ÇüÀº ¼º°ø·ü¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÁßÁõ ARF ȯÀÚ´Â ºñ°­ ¸¶½ºÅ©º¸´Ù Àü¸é ¸¶½ºÅ©°¡ ±ÇÀåµË´Ï´Ù. µû¶ó¼­ À¯·´¿¡¼­ COPD ¹× ±âŸ È£Èí±â ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±¸°­, ºñ°­, ÇÏÀ̺긮µå, ÄÚ, ÄÚ º£°³, Çï¸ä, Çìµå ±â¾î ¹× ±âŸ ¸¶½ºÅ© À¯ÇüÀº ȯÀÚÀÇ ºÒÆíÇÔ, °ø±â ´©Ãâ, ¹Ð½Ç °øÆ÷Áõ, ÇǺΠ¹ßÀû, ´« ÀÚ±Ø, ÇǺΠÆÄ±«, ¾î¸°ÀÌÀÇ ¾ó±¼ ±âÇüÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¶½ºÅ© ÇÏ´ÜÀÇ ÀÛÀº ´©ÃâÀº NIVÀÇ ¼º´É¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê½À´Ï´Ù. ±×·¯³ª ´©ÃâÀÌ Å©°Å³ª ¸¶½ºÅ©ÀÇ ´«¿¡¼­ ´©ÃâÀÌ ¹ß»ýÇÏ¸é °ÆÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÄÚ ´Ù¸®ÀÇ ÅëÁõÀº ¸¶½ºÅ©°¡ ³Ê¹« ºýºýÇϰųª »óºÎ ÇÇÆÃÀÌ ÁÁÁö ¾Ê´Ù´Â °ÍÀ» ³ªÅ¸³À´Ï´Ù. ÅëÁõÀÌ ¾ÇÈ­ µÉ ¼ö ÀÖÀ¸¹Ç·Î ¸¶½ºÅ©¸¦ ÀçÁ¶Á¤Çϰųª ±³Ã¼ÇؾßÇÕ´Ï´Ù.

NIV ¸¶½ºÅ©¿Í °ü·ÃµÈ ¿åâÀº NIVÀÇ º¸±Þ°ú ÇÔ²² ÀÓ»óÀûÀ¸·Î ½É°¢ÇÑ ¹®Á¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¿åâÀÇ ¹ß»ýÀº ÀÓ»ó °á°ú ¾ÇÈ­, ÇÕº´Áõ Áõ°¡, ÀÔ¿ø ±â°£ ¿¬Àå°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ ±Þ¼º ÁúȯÀÇ °á°ú¸¦ ¾ÇÈ­½Ãŵ´Ï´Ù.

¸¶½ºÅ©°¡ Á¦´ë·Î ¸Â´ÂÁö È®ÀÎÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ±×·¸Áö ¾ÊÀ¸¸é »ê¼Ò°¡ ´«¿¡ ´©ÃâµÇ¾î ¿°Áõ°ú °á¸·¿°À» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü¸é ¸¶½ºÅ©¸¦ »ç¿ëÇÏ¸é ±âħÀ» ¹æÇØÇÏ°í ºÐºñ¹°À» È¿°úÀûÀ¸·Î Á¦°Å ÇÒ ¼ö ¾ø½À´Ï´Ù. ¶ÇÇÑ ¹ß»ýÇÏ´Â °úµµÇÑ ¾Ð·ÂÀº ȯÀÚ°¡ ÃæºÐÇÑ È£±â·®À» »ý¼ºÇÏ´Â ´É·Â¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ±âħ ÀúÇ׿¡ ¾Ç¿µÇâÀ» ¹ÌÃÄ ºÐºñ¹° µ¿¿ø ¹× ºÐºñ¹° Àú·ù·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ NIV ¸¶½ºÅ©¿Í °ü·ÃµÈ ºÎÀÛ¿ëÀº À¯·´ ºñħ½ÀÀû ȯ±â ¸¶½ºÅ© ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÕ´Ï´Ù.

À¯·´ ÀÏ»ç°è ½ÃÀå ºÐ¼®Àº ÀÎÅÍÆäÀ̽º, ¿ëµµ, »ç¿ë¹ý, Àç·á, Å©±â, Á¦Ç° À¯Çü ¹× ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®À» °í·ÁÇÏ¿© ¼öÇàµË´Ï´Ù. ÀÎÅÍÆäÀ̽º¿¡ µû¶ó ½ÃÀåÀº ¸¶½ºÅ©¿Í ¾×¼¼¼­¸®·Î ³ª´¹´Ï´Ù. ¸¶½ºÅ©´Â ÄÚ ¸¶½ºÅ©, ¾ó±¼ ¸¶½ºÅ©, ÄÚ º£°³ ¸¶½ºÅ©, ±¸°­ ¸¶½ºÅ©, ÅäÅ» ÆäÀ̽º ¸¶½ºÅ©/Çï¸äÀ¸·Î ±¸¼ºµË´Ï´Ù. ÆäÀ̽º ¸¶½ºÅ©´Â CO2 ¹èÃâ ÆäÀ̽º ¸¶½ºÅ©¿Í ºñ¹èÃâ ÆäÀ̽º ¸¶½ºÅ©·Î ¼¼ºÐÈ­µÇ¸ç, NIV ¸¶½ºÅ©ÀÇ ¾×¼¼¼­¸®¿¡´Â ÆÈ²ÞÄ¡ ¹× ±³Ã¼¿ë ÆÈ²ÞÄ¡, È£½º, Æ©ºê, ÇǺΠÀ庮, ÄÚ ¾Æ·¡/ ÄÚ À§ Äí¼Ç, Çìµå ½ºÆ®·¦/ ±³Ã¼¿ë ±â¾î°¡ Æ÷ÇԵ˴ϴÙ. ¿ëµµº°·Î À¯·´ ºñħ½ÀÀû ÀΰøÈ£Èí±â ½ÃÀåÀº È£Èí±â´ÉÀå¾Ö, ¸¸¼ºÆó¼â¼ºÆóÁúȯ, Æó·Å, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ¿ëµµ¿¡ µû¶ó ½ÃÀåÀº ´Ù½Ã ¼Ò¾Æ°ú¿Í ¼ºÀÎÀ¸·Î ³ª´¹´Ï´Ù. À¯·´ ÀÏ»ç°è ½ÃÀåÀº Å©±âº°·Î ´ëÇü, ÁßÇü, ¼ÒÇüÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù. ¼ÒÀç¿¡ µû¶ó ½Ç¸®ÄÜ, Á©, ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù. Á¦Ç° À¯Çü¿¡ µû¶ó ÀÏȸ¿ë°ú Àç»ç¿ëÀ¸·Î ³ª´¹´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚº°·Î´Â º´¿ø, ÁßÁõ ±Þ¼º±â ÀÇ·á, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ±âŸ·Î ±¸ºÐµË´Ï´Ù. À¯·´ ºñħ½ÀÀû ÀΰøÈ£Èí±â ½ÃÀå Á¶»ç ¹üÀ§¿¡´Â ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ¿À½ºÆ®¸®¾Æ, ½ºÀ§½º ¹× ±âŸ À¯·´ ½ÃÀå ½ÇÀû Æò°¡°¡ Æ÷ÇԵ˴ϴÙ.

À¯·´¿¬ÇÕ(EU)°ú ¼¼°èº¸°Ç±â±¸(WHO)´Â À¯·´ ÀÏ»ç°è ½ÃÀå¿¡ ´ëÇÑ º¸°í¼­¸¦ ÀÛ¼ºÇÒ ¶§ Âü°íÇÑ ÁÖ¿ä 1Â÷ ¹× 2Â÷ Á¤º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå ±¸µµ

  • PEST ºÐ¼®
  • ¿¡ÄڽýºÅÛ ºÐ¼®
    • ¹ë·ùüÀÎ º¥´õ ¸®½ºÆ®

Á¦5Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ¾ïÁ¦¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ±âȸ
  • ÇâÈÄ µ¿Çâ
  • ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®

Á¦6Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå : À¯·´ ½ÃÀå ºÐ¼®

  • ºñħ½À¼º ȯ±â ¸¶½ºÅ© À¯·´ ½ÃÀå °³¿ä
  • ºñħ½À¼º ȯ±â ¸¶½ºÅ© À¯·´ ½ÃÀå : 2031³â±îÁöÀÇ ¿¹Ãø

Á¦7Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå - ¸ÅÃ⠺м® : ÀÎÅÍÆäÀ̽ºº°, 2020-2030³â

  • ¸¶½ºÅ©
  • ¾×¼¼¼­¸®

Á¦8Àå ºñħ½À¼º Àΰø È£Èí¿ë ¸¶½ºÅ© ½ÃÀå - ¾ÖÇø®ÄÉÀ̼Ǻ° ¸ÅÃ⠺м®, 2020-2030³â

  • È£Èí ±â´É Àå¾Ö
  • ¸¸¼ºÆó¼â¼ºÆóÁúȯ
  • Æó·Å
  • ±âŸ

Á¦9Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå : 2020-2030³â ¿ëµµº° ÆÇ¸Å°í ºÐ¼®

  • ¼Ò¾Æ¿ë
  • ¼ºÀοë

Á¦10Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå - ±Ô¸ðº° ¸ÅÃ⠺м®, 2020-2030³â

  • ´ëÇü
  • ÁßÇü
  • ¼ÒÇü

Á¦11Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀåºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå : ¸ÅÃ⠺м® : ¼ÒÀ纰, 2020-2030³â

  • ½Ç¸®ÄÜ
  • °Ö
  • ±âŸ

Á¦12Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå : ¸ÅÃ⠺м® : Á¦Ç° À¯Çüº°, 2020-2030³â

  • ÀÏȸ¿ë
  • Àç»ç¿ë °¡´É

Á¦13Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀåºñħ½À¼º Àΰø È£Èí¿ë ¸¶½ºÅ© ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº° ¸ÅÃ⠺м® : 2020-2030³â

  • º´¿ø
  • ÁßÁõ¡¤±Þ¼º±â ÀÇ·á½Ã¼³
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦14Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå : ÆÇ¸Å°í ºÐ¼®, 2020-2030³â : ±¹°¡º° ºÐ¼®

  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ¿µ±¹
    • ¿À½ºÆ®¸®¾Æ
    • ½ºÀ§½º
    • ±âŸ À¯·´

Á¦15Àå ¾÷°è »óȲ

  • ÇÕº´°ú Àμö
  • °è¾à, Á¦ÈÞ, ÇÕº´»ç¾÷
  • ½ÅÁ¦Ç° Ãâ½Ã
  • »ç¾÷ È®´ë¿Í ±âŸ Àü·«Àû °³¹ß

Á¦16Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ÀÇ Æ÷Áö¼Å´×°ú ÁýÁßµµ

Á¦17Àå ºñħ½À¼º ȯ±â ¸¶½ºÅ© ½ÃÀå - ÁÖ¿ä ±â¾÷ °³¿ä

  • SunMED Medical
  • ResMed
  • Armstrong Medical Ltd
  • Koninklijke Philips N.V.
  • Ambu A/S
  • Dragerwerk AG and Co. KGaA
  • DEAS S.R.L.
  • Fisher and Paykel Healthcare Limited
  • Intersurgical Ltd
  • Hamilton Medical

Á¦18Àå ºÎ·Ï

KSA 24.04.26

The Europe noninvasive ventilation masks market is expected to grow from US$ 719.83 million in 2022 to US$ 1,076.68 million by 2030; it is anticipated to record a CAGR of 5.2% from 2022 to 2030.

Non-invasive ventilation (NIV) is the delivery of oxygen (ventilation support) through a face mask, eliminating the need for an endotracheal airway. NIV provides comparable physiological benefits to conventional mechanical ventilation by reducing breathing work and improving gas exchange. The intervention is recognized as an effective treatment for respiratory failure in chronic obstructive pulmonary disease, cardiogenic pulmonary edema, and other respiratory conditions without complications, such as upper airway trauma, ventilator-associated pneumonia, respiratory muscle weakness, and sinusitis. Thus, the increasing prevalence of respiratory diseases will likely significantly impact the Europe noninvasive ventilation masks market forecast in the next few years.

Rising Prevalence of COPD Propels Europe Noninvasive Ventilation Masks Market Growth

Chronic obstructive pulmonary disease (COPD) is one of the most significant public health concerns. According to the article "Effectiveness of a home telemonitoring program for patients with chronic obstructive pulmonary disease in Germany" published by the National Library of Medicine in 2022, Germany reported ~ 6 million COPD cases. According to an article titled "What knows a frail Swiss population about chronic obstructive pulmonary disease?" published in 2021, about 400,000 people were affected by COPD in Switzerland.

Patients with underlying COPDs who suffer from exacerbation of their diseases and hypercapnic dyspnoea or respiratory failure are most likely to be successfully treated with noninvasive ventilation (NIV). NIV effectively relieves the pressure on the respiratory muscles, increases tidal volume, decreases respiratory rate, and reduces the work of diaphragmatic breathing, resulting in an improvement in oxygen supply, a decrease in hypercapnia, and an improvement in dyspnea. A COPD is ideal for NIV as the treatment is quickly reversible, and additional support can be provided.

NIV reduces the endotracheal intubation rate, length of hospital stays, complications of mechanical ventilation, and mortality for COPD patients. Recent clinical practice guidelines recommend NIV as first-line ventilatory support for treating acute respiratory failure (ARF) in COPDs. NIV masks are increasingly used to treat people suffering from COPD and respiratory failure.

NIV helps reduce intubation and mortality in patients affected by COPD exacerbation with respiratory failure. The type of mask may impact the success rate. A full-face mask is recommended over nasal masks for patients who are seriously ill and suffer from ARF. Thus, Europe's increasing prevalence of COPD and other respiratory disorders is expected to fuel the market's growth.

Oral, oronasal, hybrid, nasal, nasal pillow, helmet, headgear, and other mask types can lead to patient discomfort, air leaks, claustrophobia, skin redness, eye irritation, skin breakdown, and facial deformity in children. A small leak at the bottom of the mask does not affect NIV's performance. However, a large leak or a leak in the eye of mask can be a concern. Pain on the nose bridge indicates that the mask is too tight or is poorly fitting at the top. The mask must be readjusted or replaced, as the pain can worsen.

Pressure ulcers associated with NIV masks are a significant clinical problem due to the increasing popularity of the intervention. The development of pressure ulcers is associated with poor clinical outcomes, increased complications, and extended hospital stays, all of which aggravate the consequences of acute illness.

It is essential to make sure that the mask fits properly. Otherwise, oxygen may leak into the eyes, causing irritation and conjunctivitis. Using a full-face mask can interfere with coughing and effectively eliminate secretions. In addition, the excess pressure generated can affect the patient's ability to generate sufficient expiratory flow rates, adversely impacting the mobilization of secretions and cough resistance that leads to the retention of secretions.

Thus, side effects associated with NIV masks hamper the growth of the Europe non-invasive ventilation masks market.

The Europe noninvasive ventilation masks market analysis has been carried out by considering the following segments: interfaces, application, usage, material, size, product type, and end user. By interfaces, the market is bifurcated into masks and accessories. The masks segment consists of a nasal mask, face mask, nasal pillow mask, oral mask, and total face mask/helmets. Face mask is further sub-segmented into CO2 venting face mask and non-vented face mask. Accessories of NIV masks include elbows and replacement elbows, hoses, tubes, skin barriers, under/over the nose cushions, and head strap/replacement gears. Based on application, the Europe non-invasive ventilation masks market is segmented into respiratory dysfunction, chronic obstructive pulmonary disease, pneumonia, and others. Based on the usage, the market is further segmented into pediatrics and adults. The Europe non-invasive ventilation masks market, by size, is further segmented into large, medium, and small. Based on material, it is further segmented into silicon, gel, and others. Based on product type, the market is bifurcated into single-use and reusable. Based on end user, the market is segmented into hospitals, critical and acute care settings, ambulatory surgical centers, and others. The scope of Europe noninvasive ventilation masks market report includes assessing the market performance in the UK, Germany, France, Austria, Switzerland, and the Rest of Europe.

European Union (EU) and World Health Organization (WHO) are key primary and secondary sources referred to while preparing the report on the Europe noninvasive ventilation masks market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Non-Invasive Ventilation Masks Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Non-Invasive Ventilation Masks Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Non-Invasive Ventilation Masks Market - Europe Market Analysis

  • 6.1 Non-Invasive Ventilation Masks - Europe Market Overview
  • 6.2 Non-Invasive Ventilation Masks - Europe Market and Forecast to 2031

7. Non-Invasive Ventilation Masks Market - Revenue Analysis (USD Million) - By Interfaces, 2020-2030

  • 7.1 Overview
  • 7.2 Masks
    • 7.2.1 Nasal Mask
    • 7.2.2 Face Mask
      • 7.2.2.1 CO2 Venting
      • 7.2.3.1 Non-Vented
    • 7.2.3 Nasal Pillow Mask
    • 7.2.4 Oral Mask
    • 7.2.5 Total face Mask/Helmets
  • 7.3 Accessories
    • 7.3.1 Elbows and replacement elbows
    • 7.3.2 Hoses
    • 7.3.3 Tubes
    • 7.3.4 Skin barriers
    • 7.3.5 Under/over the nose cushions
    • 7.3.6 Head strap/replacement gears

8. Non-Invasive Ventilation Masks Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 8.1 Overview
  • 8.2 Respiratory Dysfunction
  • 8.3 Chronic Obstructive Pulmonary Diseases
  • 8.4 Pneumonia
  • 8.5 Others

9. Non-Invasive Ventilation Masks Market - Revenue Analysis (USD Million) - By Usage, 2020-2030

  • 9.1 Overview
  • 9.2 Paediatric
  • 9.3 Adult

10. Non-Invasive Ventilation Masks Market - Revenue Analysis (USD Million) - By Size, 2020-2030

  • 10.1 Overview
  • 10.2 Large
  • 10.3 Medium
  • 10.4 Small

11. Non-Invasive Ventilation Masks Market - Revenue Analysis (USD Million) - By Material, 2020-2030

  • 11.1 Overview
  • 11.2 Silicon
  • 11.3 Gel
  • 11.4 Others

12. Non-Invasive Ventilation Masks Market - Revenue Analysis (USD Million) - By Product Type, 2020-2030

  • 12.1 Overview
  • 12.2 Single Use
  • 12.3 Reusable

13. Non-Invasive Ventilation Masks Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 13.1 Overview
  • 13.2 Hospitals
  • 13.3 Critical and Acute Care Settings
  • 13.4 Ambulatory Surgical Centers
  • 13.5 Others

14. Non-Invasive Ventilation Masks Market - Revenue Analysis (USD Million), 2020-2030 - Country Analysis

  • 14.1 Europe
    • 14.1.1 Europe Non-Invasive Ventilation Masks Market Overview
    • 14.1.2 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts to 2031
    • 14.1.3 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts and Analysis - By Interfaces
    • 14.1.4 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts and Analysis - By Application
    • 14.1.5 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts and Analysis - By Usage
    • 14.1.6 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts and Analysis - By Size
    • 14.1.7 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts and Analysis - By Material
    • 14.1.8 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts and Analysis - By Product Type
    • 14.1.9 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts and Analysis - By End User
    • 14.1.10 Europe Non-Invasive Ventilation Masks Market Revenue and Forecasts and Analysis - By Countries
      • 14.1.10.1 Germany Non-Invasive Ventilation Masks Market
        • 14.1.10.1.1 Germany Non-Invasive Ventilation Masks Market, by Interfaces
        • 14.1.10.1.2 Germany Non-Invasive Ventilation Masks Market, by Application
        • 14.1.10.1.3 Germany Non-Invasive Ventilation Masks Market, by Usage
        • 14.1.10.1.4 Germany Non-Invasive Ventilation Masks Market, by Size
        • 14.1.10.1.5 Germany Non-Invasive Ventilation Masks Market, by Material
        • 14.1.10.1.6 Germany Non-Invasive Ventilation Masks Market, by Product Type
        • 14.1.10.1.7 Germany Non-Invasive Ventilation Masks Market, by End User
      • 14.1.10.2 France Non-Invasive Ventilation Masks Market
        • 14.1.10.2.1 France Non-Invasive Ventilation Masks Market, by Interfaces
        • 14.1.10.2.2 France Non-Invasive Ventilation Masks Market, by Application
        • 14.1.10.2.3 France Non-Invasive Ventilation Masks Market, by Usage
        • 14.1.10.2.4 France Non-Invasive Ventilation Masks Market, by Size
        • 14.1.10.2.5 France Non-Invasive Ventilation Masks Market, by Material
        • 14.1.10.2.6 France Non-Invasive Ventilation Masks Market, by Product Type
        • 14.1.10.2.7 France Non-Invasive Ventilation Masks Market, by End User
      • 14.1.10.3 Italy Non-Invasive Ventilation Masks Market
        • 14.1.10.3.1 Italy Non-Invasive Ventilation Masks Market, by Interfaces
        • 14.1.10.3.2 Italy Non-Invasive Ventilation Masks Market, by Application
        • 14.1.10.3.3 Italy Non-Invasive Ventilation Masks Market, by Usage
        • 14.1.10.3.4 Italy Non-Invasive Ventilation Masks Market, by Size
        • 14.1.10.3.5 Italy Non-Invasive Ventilation Masks Market, by Material
        • 14.1.10.3.6 Italy Non-Invasive Ventilation Masks Market, by Product Type
        • 14.1.10.3.7 Italy Non-Invasive Ventilation Masks Market, by End User
      • 14.1.10.4 Spain Non-Invasive Ventilation Masks Market
        • 14.1.10.4.1 Spain Non-Invasive Ventilation Masks Market, by Interfaces
        • 14.1.10.4.2 Spain Non-Invasive Ventilation Masks Market, by Application
        • 14.1.10.4.3 Spain Non-Invasive Ventilation Masks Market, by Usage
        • 14.1.10.4.4 Spain Non-Invasive Ventilation Masks Market, by Size
        • 14.1.10.4.5 Spain Non-Invasive Ventilation Masks Market, by Material
        • 14.1.10.4.6 Spain Non-Invasive Ventilation Masks Market, by Product Type
        • 14.1.10.4.7 Spain Non-Invasive Ventilation Masks Market, by End User
      • 14.1.10.5 United Kingdom Non-Invasive Ventilation Masks Market
        • 14.1.10.5.1 United Kingdom Non-Invasive Ventilation Masks Market, by Interfaces
        • 14.1.10.5.2 United Kingdom Non-Invasive Ventilation Masks Market, by Application
        • 14.1.10.5.3 United Kingdom Non-Invasive Ventilation Masks Market, by Usage
        • 14.1.10.5.4 United Kingdom Non-Invasive Ventilation Masks Market, by Size
        • 14.1.10.5.5 United Kingdom Non-Invasive Ventilation Masks Market, by Material
        • 14.1.10.5.6 United Kingdom Non-Invasive Ventilation Masks Market, by Product Type
        • 14.1.10.5.7 United Kingdom Non-Invasive Ventilation Masks Market, by End User
      • 14.1.10.6 Austria Non-Invasive Ventilation Masks Market
        • 14.1.10.6.1 Austria Non-Invasive Ventilation Masks Market, by Interfaces
        • 14.1.10.6.2 Austria Non-Invasive Ventilation Masks Market, by Application
        • 14.1.10.6.3 Austria Non-Invasive Ventilation Masks Market, by Usage
        • 14.1.10.6.4 Austria Non-Invasive Ventilation Masks Market, by Size
        • 14.1.10.6.5 Austria Non-Invasive Ventilation Masks Market, by Material
        • 14.1.10.6.6 Austria Non-Invasive Ventilation Masks Market, by Product Type
        • 14.1.10.6.7 Austria Non-Invasive Ventilation Masks Market, by End User
      • 14.1.10.7 Switzerland Non-Invasive Ventilation Masks Market
        • 14.1.10.7.1 Switzerland Non-Invasive Ventilation Masks Market, by Interfaces
        • 14.1.10.7.2 Switzerland Non-Invasive Ventilation Masks Market, by Application
        • 14.1.10.7.3 Switzerland Non-Invasive Ventilation Masks Market, by Usage
        • 14.1.10.7.4 Switzerland Non-Invasive Ventilation Masks Market, by Size
        • 14.1.10.7.5 Switzerland Non-Invasive Ventilation Masks Market, by Material
        • 14.1.10.7.6 Switzerland Non-Invasive Ventilation Masks Market, by Product Type
        • 14.1.10.7.7 Switzerland Non-Invasive Ventilation Masks Market, by End User
      • 14.1.10.8 Rest of Europe Non-Invasive Ventilation Masks Market
        • 14.1.10.8.1 Rest of Europe Non-Invasive Ventilation Masks Market, by Interfaces
        • 14.1.10.8.2 Rest of Europe Non-Invasive Ventilation Masks Market, by Application
        • 14.1.10.8.3 Rest of Europe Non-Invasive Ventilation Masks Market, by Usage
        • 14.1.10.8.4 Rest of Europe Non-Invasive Ventilation Masks Market, by Size
        • 14.1.10.8.5 Rest of Europe Non-Invasive Ventilation Masks Market, by Material
        • 14.1.10.8.6 Rest of Europe Non-Invasive Ventilation Masks Market, by Product Type
        • 14.1.10.8.7 Rest of Europe Non-Invasive Ventilation Masks Market, by End User

15. Industry Landscape

  • 15.1 Mergers and Acquisitions
  • 15.2 Agreements, Collaborations, Joint Ventures
  • 15.3 New Product Launches
  • 15.4 Expansions and Other Strategic Developments

16. Competitive Landscape

  • 16.1 Heat Map Analysis by Key Players
  • 16.2 Company Positioning and Concentration

17. Non-Invasive Ventilation Masks Market - Key Company Profiles

  • 17.1 SunMED Medical
    • 17.1.1 Key Facts
    • 17.1.2 Business Description
    • 17.1.3 Products and Services
    • 17.1.4 Financial Overview
    • 17.1.5 SWOT Analysis
    • 17.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 17.2 ResMed
  • 17.3 Armstrong Medical Ltd
  • 17.4 Koninklijke Philips N.V.
  • 17.5 Ambu A/S
  • 17.6 Dragerwerk AG and Co. KGaA
  • 17.7 DEAS S.R.L.
  • 17.8 Fisher and Paykel Healthcare Limited
  • 17.9 Intersurgical Ltd
  • 17.10 Hamilton Medical

18. Appendix

  • 18.1 Glossary
  • 18.2 About The Insight Partners
  • 18.3 Market Intelligence Cloud
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦